<DOC>
	<DOC>NCT02386761</DOC>
	<brief_summary>A phase I randomised, double-blind, placebo-controlled study of single and repeated ascending doses in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of inhaled chf 6001.</brief_summary>
	<brief_title>A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Inhaled CHF6001</brief_title>
	<detailed_description>To assess the safety and tolerability of single and repeated ascending doses of CHF 6001 in healthy volunteers and to investigate the pharmacokinetic (PK) profile of CHF 6001 and its metabolites CHF 5956 and CHF 6095.</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<criteria>Main Inclusion Subject's written informed consent obtained prior to any studyrelated procedure Male and female Caucasian healthy volunteers aged 1855 years inclusive Vital signs:Subjects aged 1845: Diastolic BP 4090, Systolic BP 90140 Subjects aged 4555: Diastolic BP 4090, Systolic BP 90150 (as mean of three measures performed after at least 5 minutes of resting); checked at screening visit and Day 1 12lead digitised Electrocardiogram (12lead ECG) considered as normal (40≤Heart rate≤110bpm,120 ms ≤ PR ≤ 210 ms, QRS ≤ 120 ms, QTcF ≤ 450 ms for males and ≤ 470ms for females) checked at screening visit and Day 1 Lung function measurements within normal limits: FEV1 &gt; 80% of predicted normal value (according to the Global Lung Function Initiative, ERS Task Force Lung Function Reference Values (1,2) ) and FEV1/FVC ratio &gt; 0.70 Main Exclusion: Pregnant or lactating women Clinically significant cardiac abnormalities Any clinically relevant abnormal laboratory values</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>